Table 2 Baseline characteristics
Variable | Group 1: HFpEF (n = 77) | Group 2: Diastolic Dysfunction (n = 77) | P-value |
|---|---|---|---|
Age (years) | 68.6 ± 9.9 | 68.5 ± 9.9 | 0.96 |
Gender (% Female) | 67.5 | 67.5 | 1.0 |
Race (% African American) | 30.5 | 30.5 | 1.0 |
Body Surface Area (m2) | 1.97 ± 0.31 | 1.93 ± 0.24 | 0.31 |
Tobacco Use (%) | 56.2 | 60.3 | 0.61 |
Alcohol Use (%) | 49.3 | 58.0 | 0.27 |
Hypertension (%) | 88.3 | 72.7 | 0.02 |
Diabetes (%) | 55.8 | 27.3 | 0.0002 |
Coronary Artery Disease (%) | 61.0 | 39.0 | 0.01 |
Atrial Fibrillation (%) | 40.3 | 16.9 | 0.003 |
Chronic Kidney Disease (%) | 63.6 | 24.7 | <0.0001 |
NT-proBNP (pg/mL) | 9810 ± 14308 | 2148 ± 3026 | 0.07 |
GFR (mL/min/1.73 m2) | 44.8 ± 20.0 | 57.9 ± 23.6 | 0.002 |
Systolic BP (mmHg) | 145.9 ± 29.7 | 140.9 ± 21.0 | 0.73 |
Diastolic BP (mmHg) | 70.7 ± 15.7 | 74.6 ± 10.9 | 0.37 |
Pulse Pressure (mmHg) | 75.6 ± 21.5 | 66.3 ± 16.7 | 0.17 |
Beta Blockers (%) | 62.3 | 72.7 | 0.21 |
Calcium Channel Blockers (%) | 28.6 | 28.6 | 1.0 |
ACE Inhibitors (%) | 16.9 | 26.0 | 0.13 |
Angiotensin Receptor Blockers (%) | 18.2 | 23.4 | 0.45 |